To advance drug discovery for cardiovascular patients, new pre-clinical models and quantification methods are needed to improve clinical predictivity. This thesis aims to explore several approaches to bringing new solutions for disease modeling which reflect the human heart. Firstly, we review the current status of the Heart-on-chip (HoC) field and the cutting edge (bio)materials which enable more physiologically relevant culture methods for stem cell-derived cardiomyocytes (hiPSC-CMs). Then, we use a polydimethylsiloxane chip to culture hiPSC-CM, hiPSC-endothelial cells and hiPSC-cardiac fibroblasts combined with a microfluidic flow-channel to mimic physiological blood flow. Subsequently, we fabricated and tested a platform for 3D-culture ...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
Human induced pluripotent stem cells (hiPSCs) can be used to generate various cell types in the huma...
A scientific milestone that has tremendously impacted the cardiac research field has been the discov...
The generation of cardiomyocytes from human induced pluripotent stem cells (hiPSCs) provides a sourc...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
Development of new drugs is of high interest for the field of cardiac and cardiovascular diseases, w...
Cardiovascular disease (CVD) is the most prevalent health problem in the world, and the high mortali...
Studying diseases or effects of new drugs on the human body is challenging, not least because of the...
<p>The overall increase in cardiovascular diseases and, specifically, the ever-rising exposure...
Cardiovascular disorders remain a critical health issue worldwide. While animals have been used exte...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
Human induced pluripotent stem cells (hiPSCs) can be used to generate various cell types in the huma...
A scientific milestone that has tremendously impacted the cardiac research field has been the discov...
The generation of cardiomyocytes from human induced pluripotent stem cells (hiPSCs) provides a sourc...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
Development of new drugs is of high interest for the field of cardiac and cardiovascular diseases, w...
Cardiovascular disease (CVD) is the most prevalent health problem in the world, and the high mortali...
Studying diseases or effects of new drugs on the human body is challenging, not least because of the...
<p>The overall increase in cardiovascular diseases and, specifically, the ever-rising exposure...
Cardiovascular disorders remain a critical health issue worldwide. While animals have been used exte...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...